Stockscreener 앱 받기
3.63
0.00%
0.01
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - simplywall.st
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares - TradingView
Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech - DirectorsTalk Interviews
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead (NASDAQ:RXRX) - Seeking Alpha
RXRX: Integrated platform, strong partnerships, and disciplined pipeline drive innovation and growth - TradingView
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure - Markets Mojo
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline - Sahm
Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview - marketscreener.com
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis - Sahm
Recursion Pharmaceuticals Opens with 11.05% Gain Despite Recent Declines - Markets Mojo
Recursion Pharmaceuticals (RXRX) hits clinical milestones as 2025 revenue grows to $74.7M - MSN
Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M - Yahoo Finance
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026 - Meyka
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue - simplywall.st
Recursion Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-02-25 - Seeking Alpha
Recursion Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Recursion Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate - timothysykes.com
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 EPS and Revenue Estimates - MEXC
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic (NASDAQ:RXRX) - Seeking Alpha
BofA cuts Recursion Pharmaceuticals stock price target on launch timing - Investing.com
Recursion (RXRX) Q4 2025 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ) - Seeking Alpha
Recursion’s AI-Enabled Drug Discovery Wins Spotlight at NVIDIA’s Conference - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results - MarketBeat
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - The Globe and Mail
What's Behind The Jump In Recursion Pharmaceuticals Stock? - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Recursion Pharmaceuticals Receives Spotlight with AI-driven Innovations at NVIDIA’s GTC - StocksToTrade
Recursion Q4 2025 slides: AI platform delivers first clinical proof-of-concept - Investing.com UK
Earnings call transcript: Recursion Pharmaceuticals beats Q4 2025 forecasts - Investing.com
This $4 Stock Could Be Your Ticket to Millionaire Status - AOL.com
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c) - TipRanks
Recursion Pharmaceuticals earnings beat by $0.09, revenue topped estimates - Investing.com UK
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion Highlights AI Validation, Extends Cash Runway to 2028 - TipRanks
Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises - marketscreener.com
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - markets.businessinsider.com
Recursion Pharmaceuticals: Fourth Quarter Financial Highlights - Bitget
Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Recursion Reports Clinical Milestones and Financial Results for Q4 2025, Including AI-Driven Insights Leading to Patient Outcomes - Quiver Quantitative
RECURSION PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
RXRX: AI-driven platform validated clinically, strong partner milestones, and cash runway into 2028 - TradingView
AI drug maker Recursion (NASDAQ: RXRX) grows revenue, narrows Q4 loss - Stock Titan
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (2026-02-25) - Seeking Alpha
Recursion Pharmaceuticals Q4 Earnings Report: What Investors Need to Know - Sahm
ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 - Benzinga
Recursion Pharmaceuticals's Earnings Outlook - Benzinga
Recursion Pharmaceuticals in focus: Can earnings validate AI drug model? By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals in focus: Can earnings validate AI drug model? - Investing.com
Recursion Pharmaceuticals, Inc. $RXRX Position Trimmed by Vestmark Advisory Solutions Inc. - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Evaluating a Potential 105% Upside in the Biotech Sector - DirectorsTalk Interviews
Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Report Pre - GuruFocus
0.50%
자본화:
|
볼륨(24시간):